NEW YORK, Jan. 25, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
The global biologics market is valued at an estimated $149 billion in 2010 and is expected to reach $239 billion by 2015, a compound annual growth rate (CAGR) of 9.9% from 2010-2015. Driving this growth is the need for a more extensive drug pipeline, attractive targets against challenging diseases, a push to pursue biosimilars, and enabling manufacturing technologies that reduce the cost to produce profitable products.
Monoclonal antibodies (mAbs) comprised 31.9% of the 2009 market, or $43 billion. The mAb segment is expected to increase at the fastest rate within the total biologics market to $86 billion by 2015, from a value of $48 billion in 2010, a compound annual growth rate (CAGR) of 12.4%.
Therapeutic proteins were nearly half the 2009 market, or 48.8%, and the largest segment at $66 billion. The therapeutic protein segment is valued at $72 billion in 2010 and expected to increase at an 8.2% a compound annual growth rate (CAGR) to reach $107 billion in 2015.
STUDY GOALS AND OBJECTIVESThis study provides a comprehensive analysis of biologics, or biopharmaceuticals, on a global basis. Its aim is to provide a range of information, from detailed product analyses within disease subsegments to overall industry trends, in order to quantify and qualify the market for therapeutic drug products in the biologics segment. Segments are forecast on a global basis. Forecasts and trends are developed from a cross-reference of data points, gleaned from proprietary industry sources, company publications, industry benchmarking, and other divergent data sources to arrive at a cogent and coordinated forecast.
REASONS FOR DOING THE STUDYThe biologics, or biopharmaceutical, therapeutic market is wide ranging and has important implications for the future of medicine and industry advancement. For companies with an effective strategy, market opportunity awaits. Importantly, the ability to develop an effective strategy begins with where opportunity exists and ends with how to effectively execute to capture profit from opportunity.
Market growth has been spurred by the need for a more extensive pipeline by drug companies, attractive targets against challenging diseases, a push by companies to pursue biosimilars, and enabling manufacturing technologies that reduce the cost to produce profitable products.
This study deeply investigates one of the most important market drivers: specific product reviews of those programs expected to dominate the biopharmaceutical marketplace in the coming years.
This report seeks to address the critically important topics of analyzing a changing market dynamic, emerging players and technologies, strategies for accessing emerging markets, and specific disease segments and geographies in order to allocate resources and make effective decisions.
SCOPE OF REPORTCurrent and projected product forecasts during the forecast period (2010 to 2015) are discussed. As well, new products approved in 2009 and 2010 by the Food & Drug Administration (FDA) and European Medicines Agency EMA and those products expected to be approved within the forecast period are projected within their respective segment. Figures for 2010 are projected estimates, except where actual results have been reported due to the release timing of the report. For large markets segments such as mAb, therapeutic proteins, and vaccines, specific mechanisms of action are discussed in detail. For example, the trend of increased use of Vascular Endothelial Growth Factor (VEGF) inhibitors as a first-line therapy for multiple disease states such as colorectal cancer and the ophthalmic disease wet Age-Related Macular Degeneration (AMD) are discussed.
SCOPE OF REPORT (Continued)
The report includes analysis of leading and emerging competitors in the current worldwide cardiovascular market. Profiles of manufacturers of leading products as well as biotechnology companies with novel products in development are analyzed to define their specific product strategies employed. This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products and technologies are influencing the current standard of care. Detailed profiles of current market leaders are discussed, as well as companies with innovative products poised to advance within the forecast period.
Market figures are based on revenues at the manufacturers' level and are projected at 2010-dollar value. Inflation is not computed into the projection figures. Trends are assessed based on projected sales for existing products, new product introductions, expanded indications for existing products, and projected changes in the prevalence, diagnosis, and scripting rates for certain diseases.
Included in this report are forecasts by product, product category, and by company from 2009 through 2015. The study is arranged to offer an overview of the cardiovascular market accompanied by product, company, geography, and mechanism of action with forecasts broken down and covered by geographic region or country. Virtually the entire globe is covered to include prevalence data for each disease subsegment.Excluded from this report are over-the-counter (OTC) medications and other consumables that do not require a physician's prescription.
Sales figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies.
All market share data presented is on a global basis unless specifically noted. INTENDED AUDIENCEThis report is an invaluable tool for business planners, acquisitions specialists, licensing strategists, product managers, market research analysts, investors, investor consultants, and anyone interested in the cardiovascular market, its products, its industry participants, and its future.
The importance of identifying overall market trends, product opportunities, emerging geographies, M&A opportunities, and insights that provide guidance for sales growth or defensive moves cannot be overstated for a variety of constituents, including:
Established companies in the industry shall benefit from the contents, including corporate strategy, sales and marketing, business development, and R&D.
Emerging biotechnology players in the segment must understand specific opportunities for out-licensing, originating from the elements of differentiation of their therapeutic drug as compared to leading, competitive, and emerging therapies. As well, market forecasts can support investment, provided a thorough and detailed substantiation is provided for the market forecast, as is found in this study.
Investment firms evaluating candidates for venture capital or hedged investments will gain insights as to the opportunity and risks that are being encountered in the industry in a product and company specific analysis.
Equity analysts are provided detailed forecasts for the next 5 years, substantiated by quantitative analysis that can support further analysis to product and company forecasts over the short and long run.
METHODOLOGY AND INFORMATION SOURCESBoth primary and secondary research methodologies were used in preparing this report. In-depth interviews were conducted with leading experts in the field who are executives in companies, industry analysts, and leading medical practitioners in the field.
Information to prepare this report was obtained from participating and emerging companies in the cardiovascular area; American Heart Association; and the National Heart, Lung, and Blood Institute; published in medical journals such as the American Heart Journal, Circulation, Journal of Cardiovascular Pharmacology, Lancet, and others; the World Health Organization and other government agencies; literature searches; annual reports; 10Ks; and others. Population estimates are based on those reported by the international database of the U.S. Census Bureau.
Current and historical revenue figures for individual products have been sourced from company disclosures that exist in the public domain or from government sources.
To order this report:: Biologic Therapeutic Drugs: Technologies and Global Markets
Copyright©2010 PR Newswire.
All rights reserved